Lilly is seeking approval for donanemab in early-stage Alzheimer's, and is hoping to get a speedy FDA green light on the back of amyloid clearance data as a surrogate marker for clinical efficacy ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

However, its approval has been met with controversy due to debates over its clinical efficacy and associated risks. Donanemab, developed by Eli Lilly, is another promising monoclonal antibody ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...